Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | PDE6D | O43924 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8846682 | 0.89 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2219461 | 0.89 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL5698777 | 0.89 | HMGCR (0.49) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL697202 | 0.89 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL697201 | 0.89 | HMGCR (0.62) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10305922 | 0.88 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL696979 | 0.88 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL696978 | 0.88 | HMGCR (0.64) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL10129258 | 0.87 | HMGCR (0.47) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL22894711 | 0.87 | HMGCR (0.60) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518035-A | Rosuvastatin tert-butylamine salt and preparation method thereof | 安徽鼎旺医药有限公司 | 2020-08-11 | — | — | CN | claimed |
| EP-2788342-B1 | PROCESS FOR THE PREPARATION OF A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-01-24 | — | — | EP | claimed |
| EP-3022213-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LTD (IN) | 2017-06-21 | — | — | EP | claimed |
| US-9518028-B2 | Process for the preparation of Rosuvastatin calcium and preparation of its novel intermediates | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-12-13 | — | — | US | claimed |
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| EP-2665722-B1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | DSM SINOCHEM PHARM NL BV (NL) | 2016-08-17 | — | — | EP | claimed |
| EP-2576518-B1 | IMPROVED PROCESS FOR THE PREPARATION OF PROPENAL INTERMEDIATE AND DERIVATIVES THEREOF | PHARMATHEN SA (GR) | 2016-08-10 | — | — | EP | claimed |
| EP-3022213-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | Suven Life Sciences Limited (IN) | 2016-05-25 | — | — | EP | claimed |
| US-9150562-B2 | Process for the preparation of diol sulfones | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2015-10-06 | — | — | US | claimed |
| EP-2665721-B1 | METHYLTETRAZOLE SULFIDES AND SULFONES | DSM SINOCHEM PHARM NL BV (NL) | 2015-07-08 | — | — | EP | claimed |
| WO-2008059519-A2 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES OF ROSUVASTATIN | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2008-05-22 | — | — | WO | claimed |
| CN-101100459-A | Method for preparing (E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-prop-2-en-1-ol, intermediate thereof and preparation method for the intermediate | ANHUI QINGYUN PHARMACEUTICAL A (CN) | 2008-01-09 | — | — | CN | claimed |
| WO-2007074391-A2 | PREPARATION OF A KEY INTERMEDIATE IN THE SYNTHESIS OF ROSUVASTATIN | KHAMAR BAKULESH MAFATLAL (IN) | 2007-07-05 | — | — | WO | claimed |
| US-20070142418-A1 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICALS USA, INC. | 2007-06-21 | — | — | US | claimed |
| US-7179916-B2 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-02-20 | — | — | US | claimed |
| US-20060149065-A1 | Process for the preparation of rosuvastatin | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2006-07-06 | — | — | US | claimed |
| US-20060089501-A1 | Process for the preparation of rosuvastatin | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-04-27 | — | — | US | claimed |
| CN-1742000-A | Process for the preparation of rosuvastatin | RANBAXY LAB LTD (IN) | 2006-03-01 | — | — | CN | claimed |
| EP-1578733-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-28 | — | — | EP | claimed |
| WO-2004052867-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304468-A1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM AND PREPARATION OF ITS NOVEL INTERMEDIATES | ORAI1, RYR1, CACNA1E | HMGCR 4/4885ALDH1A1 1749/4885CYP3A4 141/4885 |
| US-20060089501-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, CETP | HMGCR 1/4885ALDH1A1 2920/4885CYP3A4 24/4885 |
| US-20060149065-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, CETP | HMGCR 1/4885ALDH1A1 3211/4885CYP3A4 42/4885 |
| US-20070142418-A1 | Process for the preparation of rosuvastatin | HMGCR, PCSK9, FDPS | HMGCR 1/4885ALDH1A1 2996/4885CYP3A4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.